Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3929249 | 0.85 | JAK2 (0.50) | JAK2IGF1R | |
| SCHEMBL3921809 | 0.85 | JAK2 (0.49) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3924884 | 0.85 | JAK2 (0.48) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3924562 | 0.83 | JAK2 (0.48) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3933782 | 0.83 | JAK2 (0.48) | JAK2IGF1R | |
| SCHEMBL3924843 | 0.83 | JAK2 (0.47) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3926122 | 0.83 | JAK2 (0.47) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3926802 | 0.83 | JAK2 (0.47) | JAK2IGF1R | |
| SCHEMBL3932566 | 0.82 | JAK2 (0.49) | JAK2IGF1RCCNE2CCNE1CDK2 | |
| SCHEMBL3926860 | 0.82 | JAK2 (0.46) | JAK2IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | JAK2 1/4885IGF1R 556/4885CCNE2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.